Skip to main content

Table 1 Basic clinical data

From: Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study

Group Obese T2D Obese/T2D
Condition Norm. Hyper. Norm. Hyper. Norm. Hyper.
Basic clinical data
 n 58 71 41 74 42 67
 Age (years) 48 ± 2.0 54 ± 1.6 68 ± 1.9ǂǂǂ 68 ± 1.0ǂǂǂ 60 ± 1.9ǂǂǂ 65 ± 1.2ǂǂǂ
 Female  % 59 52 40 43 53 48
 BMI (kg/m2) 34 ± 0.77 37 ± .74 26 ± .40ǂǂǂ 26 ± 0.47ǂǂǂ 36 ± .71××× 36 ± 0.74×××
 Height (cm) 166 ± 1.4 167 ± 1.1 171 ± 1.7 170 ± 1.2 166 ± 1.9 170 ± 1.4
 Heart rate (bpm) 74 ± 1.7 73 ± 1.7 71 ± 2.4 71 ± 2.0 76 ± 2.6 72 ± 1.8
 Systolic BP (mmHg) 127 ± 1.6 159 ± 3.0*** 128 ± 1.6 164 ± 2.0*** 128 ± 1.6 161 ± 2.0***
 Diastolic BP (mmHg) 78 ± 1.1 93 ± .77*** 75 ± 1.2 95 ± .52*** 76 ± 1.5 94 ± 1.5***
 PP (mmHg) 49 ± 1.4 66 ± 2.8*** 52 ± 1.7 69 ± 1.9*** 53 ± 2.5 68 ± 2.2***
 Glucose (mmol/l) 5.2 ± .10 5.2 ± 0.14 8.4 ± 0.49ǂǂǂ 8.5 ± 0.51ǂǂǂ 11 ± 0.72ǂǂǂ 9.1 ± 0.43ǂǂǂ
 Cholesterol (mmol/l) 5.1 ± .24 4.7 ± 0.24 4.1 ± 0.3 4.0 ± 0.16 4.1 ± .22 3.9 ± 0.11
 HDL-C (mmol/l) 1.3 ± .07 1.5 ± 0.13 1.2 ± 0.09 1.2 ± .04 1.2 ± 0.12 1.2 ± 0.05
 LDL-C (mmol/l) 3.1 ± .23 2.6 ± 0.28 2.2 ± 0.21ǂ 1.9 ± 0.11ǂ 1.9 ± 0.16ǂ 1.8 ± 0.10ǂ
 Triglycerides (mmol/l) 1.9 ± 1.3 1.6 ± 0.13 2.0 ± 0.34 1.9 ± 0.16 2.4 ± 0.33 2.4 ± 0.20
History anti-hyperglycaemic and anti-hypertensive medication (%)
 Biguanides 8.62 1.41 26.83ǂǂ 47.30ǂǂ 47.30ǂǂǂ 50.72ǂǂ
 DPP-4 inhibitors 0 0 4.88ǂǂ 6.76ǂǂ 0% 7.46ǂǂ
 Sulphonylureas 0 0 17.07ǂǂ 41.89ǂǂ 33.33ǂǂ 41.79ǂǂ
 Insulin 0 0 24.39ǂǂ 16.22ǂǂ 40.48ǂǂ 25.37ǂǂ
 ACE inhibitors 0 16.90*** 0 33.78*** 0 46.27***
 Ang II antagonists 0 15.14*** 0 20.27*** 0 19.40***
 Beta-blockers 0 18.31*** 0 49.32*** 0 58.21***
 Ca2+ channel blockers 0 11.27*** 0 14.86*** 0 11.94***
  1. *** p < 0.001 vs same group, different condition, ǂ p < 0.05, ǂǂ p < 0.01, ǂǂǂ p < 0.001 vs obese group, same condition, ××× p < 0.001 vs T2D group, same condition